Patupilone (Epothilone B)

For research use only. Not for use in humans.

目录号:S1364 别名: EPO906 中文名称:埃博霉素B,帕土匹龙

Patupilone (Epothilone B) Chemical Structure

CAS No. 152044-54-7

Patupilone (EPO906, Epothilone B)是一种紫杉醇样microtubule稳定剂,EC0.01为1.8 μM。Phase 2。

规格 价格 库存 购买数量  
RMB 810.81 现货
RMB 972.58 现货
RMB 1716.25 现货
RMB 3867.62 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Patupilone (Epothilone B)发表文献13篇:

客户使用该产品的4个实验数据:

  • Matrigel invasion assay of H1299 cells treated with SDF-1α or SDF-1α plus Epothilone B prior to 0 or 2 Gy irradiation. After the treatment for 12 h, the H1299 cells that migrated to the bottom surface of the membrane were stained with Giemsa, and the number of migrated cells was calculated manually.

    Oncotarget, 2015, 6(13):10893-907.. Patupilone (Epothilone B) purchased from Selleck.

  • Combination treatment with epothilone B and ABT-737 inhibited PI3K/AKT/mTOR pathway. SKOV-3 cells were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination, OVCAR-8 cells were treated with epothilone B (0.3 nM), ABT-737 (3 μM), or the combination, SGC-7901 were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination. Cells were exposed to compounds for 48 h, after which protein extracts were immunoblotted with specified antibodies for p-4E-BP-1, p-mTOR, p-AKT, caspase-3, PARP and β-actin.

    J Cancer Res Clin Oncol, 2016, 142(11):2281-9.. Patupilone (Epothilone B) purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Epothilone B for 48 h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Patupilone (Epothilone B) purchased from Selleck.

  • Combination treatment with epothilone B and ABT-737 inhibited PI3K/AKT/mTOR pathway. SKOV-3 cells were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination, OVCAR-8 cells were treated with epothilone B (0.3 nM), ABT-737 (3 μM), or the combination, SGC-7901 were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination. Cells were exposed to compounds for 48 h, after which protein extracts were immunoblotted with specified antibodies for p-4E-BP-1, p-mTOR, p-AKT, caspase-3, PARP and β-actin.

    J Cancer Res Clin Oncol, 2016, 142(11):2281-9. Patupilone (Epothilone B) purchased from Selleck.

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

产品描述 Patupilone (EPO906, Epothilone B)是一种紫杉醇样microtubule稳定剂,EC0.01为1.8 μM。Phase 2。
特性 Epothilone B是类似紫杉醇的抗癌常规化合物,诱导微管蛋白聚合。
靶点
Tubulin [1]
(Cell-free assay)
1.8 μM(EC0.01)
体外研究

Epothilone B 比 Epothilone A活性高。Epothilone B 的EC0.01为1.8 nM。Epothilone B 作用于HCT116细胞,有效抑制细胞增殖,IC50为0.8 nM。[1] Epothilone B 作用于KB3-1, KBV-1, Hela,和 Hs578T细胞,诱导细胞周期停顿,且具有细胞毒性,IC50为3 nM 到92 nM。Epothilone B与紫杉醇竞争性与微管结合,IC50为3.3 μM。[2] 3.5 nM Epothilone B 作用于过量表达GFP-α-微管蛋白的MCF-7细胞, 充分抑制微管动力学。同时,Epothilone B诱导有丝分裂停滞,IC50 为3.5 nM。[3] Epothilone B 作用于多发性骨髓瘤(MM)细胞,包括RPMI 8226, U266, MM.1S, LR5,和 MR20,直接抑制细胞增殖,IC50为1 nM到 10 nM。10 nM Epothilone B也诱导细胞周期停滞和细胞凋亡。 [4]最新研究显示, 5 nM–100 nM Epothilone B作用于卵巢癌 Hey细胞,增强表面上皮细胞粘附抗原(EpCAM)。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LC-2-ad cell M3jK[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NELJdXdKdmirYnn0bY9vKG:oIHj1cYFvKEyFLUKtZYQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njd5ZT2wOkDPxE1? NFfWXGtUSU6JRWK=
human A431 cell NV3nPI5ET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVfJcohq[mm2aX;uJI9nKGi3bXHuJGE1OzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17Lki2[U0xPiEQvF2= MX;TRW5ITVJ?
human SW1710 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUjJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNVRmNTB3IN88US=> M3Hj[HNCVkeHUh?=
human Daoy cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYLzWJdoUW6qaXLpeIlwdiCxZjDoeY1idiCGYX;5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZnwxIxiSVO1NF0zNjd|ZT2wOUDPxE1? MoexV2FPT0WU
human BFTC-905 cell M4jrNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUHINodZUW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwOUnlMVA2KM7:TR?= M{fpZ3NCVkeHUh?=
human A375 cell MoryS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmLXTY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NXWtNFUh|ryP MVnTRW5ITVJ?
human RKO cell NWHDUYNsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1jaO2lvcGmkaYTpc44hd2ZiaIXtZY4hWkuRIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj60O4UuODVizszN MVLTRW5ITVJ?
human KYSE-510 cell NF35WI5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFLWTW5KdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOVExKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5|OHWtNFUh|ryP M1;Zd3NCVkeHUh?=
human HLE cell NVzJcYFTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoqyTY5pcWKrdHnvckBw\iCqdX3hckBJVEViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD16LkK2[U0xPSEQvF2= M1jaN3NCVkeHUh?=
human MCF7 cell MnXqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIrtNIJKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlY3\S1yNTFOwG0> MonHV2FPT0WU
human 786-0 cell Mnq1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFG5ZWZKdmirYnn0bY9vKG:oIHj1cYFvKDd6Nj2wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOSCwTR?= MmPrV2FPT0WU
human TE-8 cell NEOwT2lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGPqWmtKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOSCwTR?= MlzUV2FPT0WU
ovarian carcinoma 1A9 cell M370SGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mmr2TY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3Rib4\hdolidiClYYLjbY5wdWFiMVG5JINmdGxiZ4Lve5Rp M1HNblE3OTN2OUK4
human PANC-03-27 cell NIDi[3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJHBCVkNvMEOtNlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF|MjFOwG0> NIrD[oxUSU6JRWK=
human VMRC-RCZ cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1fJUmlvcGmkaYTpc44hd2ZiaIXtZY4hXk2UQz3SR3oh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF|NjFOwG0> M3eyVnNCVkeHUh?=
human IGROV-1 cell NIradodIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4KzdWlvcGmkaYTpc44hd2ZiaIXtZY4hUUeUT2[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTV4IN88US=> M37kVnNCVkeHUh?=
human MG-63 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVjS[nBKUW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTZ3IN88US=> Mo\nV2FPT0WU
human SIG-M5 cell NYjudZJFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoXMTY5pcWKrdHnvckBw\iCqdX3hckBUUUdvTUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE3QSEQvF2= M1\YVHNCVkeHUh?=
human NCI-H650 cell NYLrNos{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkWwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPyEQvF2= NH2zOo9USU6JRWK=
human PSN1 cell NEDEXIRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoPkTY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xO|Mh|ryP NU\JSVNJW0GQR1XS
human PA-1 cell MonJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYf1TWU4UW6qaXLpeIlwdiCxZjDoeY1idiCSQT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPzRizszN M{i4ZXNCVkeHUh?=
KB-8511 cells M2f6bGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXu3NkBp MXjDc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIHnubIljcXRidHjlJIdzd3e2aDDv[kBx[WOuaYThfIVtNXKnc3nzeIFvfCCqdX3hckBmeGmmZYLtc4llKGOjcnPpco9u[SClZXzsd{BMSi16NUGxJIJ6KDVyIIDldoNmdnRiKEeyJIhzKGW6cH;zeZJmMSxiSVO1NF0xNjF6IN88US=> NWnncJhtOTFzM{OwPFY>
KB-31 cells M{TMOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnXPO|IhcA>? NU\KXZBSS2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JJRp\SCpcn;3eIghd2ZicHHjcIl1[XinbD3z[Y5{cXSrdnWgbJVu[W5iZYDp[IVzdW:rZDDjZZJkcW6xbXGgZ4VtdHNiS1KtN|Eh[nliNUCgdIVz[2WwdDCoO|IhcHJiZYjwc5N2emVr M4nEdFEyOTN|MEi2
human BHY cell NHjaS|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXP5eZV{UW6qaXLpeIlwdiCxZjDoeY1idiCESGmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE6PSCwTR?= MVHTRW5ITVJ?
human BB30-HNC cell NUe4V5pVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVrJcohq[mm2aX;uJI9nKGi3bXHuJGJDOzBvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zODFizszN MYfTRW5ITVJ?
human HOS cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVrRPIlYUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIyPSEQvF2= M{PaS3NCVkeHUh?=
human 639-V cell MoO5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXSxNGFyUW6qaXLpeIlwdiCxZjDoeY1idiB4M{mtWkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjF6IN88US=> NUH2VYNkW0GQR1XS
human ES1 cell  NF;qUWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHVTY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKyNUDPxE1? NGfZeIJUSU6JRWK=
human TE-15 cell  Mly4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{TIV2lvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIzPSEQvF2= MoHHV2FPT0WU
human LXF-289 cell M{nMcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NI\scZFKdmirYnn0bY9vKG:oIHj1cYFvKEy[Rj2yPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ5NzFOwG0> NELqU4VUSU6JRWK=
human CAL-12T cell M1TYdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1zMmSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{QSEQvF2= M4H6cnNCVkeHUh?=
human T84 cell MmLES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFWze|VKdmirYnn0bY9vKG:oIHj1cYFvKFR6NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlQh|ryP NFnH[IxUSU6JRWK=
human KYSE-450 cell NXvlN2Y5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGTrN|dKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOFUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{Nkeg{txO NYC1dJJZW0GQR1XS
human LCLC-103H cell M1jjSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWPJcohq[mm2aX;uJI9nKGi3bXHuJGxEVENvMUCzTEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzFibl2= M2jXRXNCVkeHUh?=
human NCI-H810 cell M2rmWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KOEGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OjJizszN NHr2W|VUSU6JRWK=
human HUTU-80 cell NILRdW5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml\3TY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OjhizszN NE\EfphUSU6JRWK=
human NCI-H460 cell Mn25S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNE[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzNizszN NIX0RXFUSU6JRWK=
human HGC-27 cell NGLudWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXjJcohq[mm2aX;uJI9nKGi3bXHuJGhISy1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M5KM7:TR?= MYTTRW5ITVJ?
human HSC-2 cell NILQWIRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnfrTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|Y{KG6P MmDzV2FPT0WU
human IA-LM cell NITxcnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGlCNUyPIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zPVMh|ryP NXLRcWh[W0GQR1XS
human HMV-II cell NXfNXW1nT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGhOXi2LSTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|k1KM7:TR?= MYHTRW5ITVJ?
human COLO-679 cell NITVbIpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVTJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNke5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTRizszN NWrUXoJNW0GQR1XS
human NCI-H2122 cell NV;kXmE6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH63UWpKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlEzOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEGg{txO MXvTRW5ITVJ?
human CAL-39 cell NF;iR2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkeyTY5pcWKrdHnvckBw\iCqdX3hckBESUxvM{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQyOSEQvF2= NF\uSmlUSU6JRWK=
human SW954 cell MlXOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYLKepJvUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m1OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDN4IN88US=> M{GzXHNCVkeHUh?=
human LCLC-97TM1 cell NHv1UmhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGxEVENvOUfUUVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR2NDFOwG0> NFHGfYdUSU6JRWK=
human KYSE-270 cell NHTSeJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVrW[HByUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVI4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNES1JO69VQ>? MojEV2FPT0WU
human NB13 cell M1\NXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mo\3TY5pcWKrdHnvckBw\iCqdX3hckBPSjF|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60OFch|ryP M3fRd3NCVkeHUh?=
human SK-LMS-1 cell M4LJSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlL3TY5pcWKrdHnvckBw\iCqdX3hckBUUy2OTWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjR4IN88US=> MlKxV2FPT0WU
human SW620 cell M1O5OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1TpWWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d4MkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlY1QCEQvF2= NXzVXFBpW0GQR1XS
human HCT-15 cell MlLoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX;IXI9vUW6qaXLpeIlwdiCxZjDoeY1idiCKQ2StNVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjdzNzFOwG0> M2XTcHNCVkeHUh?=
human DU-145 cell Ml;vS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mne4TY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlczOSEQvF2= NFzTcZVUSU6JRWK=
human ST486 cell NXG4dVN5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYPJcohq[mm2aX;uJI9nKGi3bXHuJHNVPDh4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63NlEh|ryP MkTFV2FPT0WU
human A427 cell NUTrdFQ{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHrMV5lKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlgzQCEQvF2= MYfTRW5ITVJ?
human HT-1080 cell NX;QTG1wT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn\LTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zMEiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45PDJizszN NEDQ[nRUSU6JRWK=
human NCI-H2009 cell NGLCdHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEThXpNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlAxQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOE[yJO69VQ>? NV7POolFW0GQR1XS
human SK-LU-1 cell NGjTemVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIDPZYJKdmirYnn0bY9vKG:oIHj1cYFvKFONLVzVMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh4NjFOwG0> M4XwSnNCVkeHUh?=
human SCC-4 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFHKZZdKdmirYnn0bY9vKG:oIHj1cYFvKFOFQz20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45PzdizszN NILEOZZUSU6JRWK=
human NCI-H1299 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2LrVmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNlk6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56ODFOwG0> M17CUHNCVkeHUh?=
human NH-12 cell M2TpUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkXjTY5pcWKrdHnvckBw\iCqdX3hckBPUC1zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFkyKM7:TR?= NWHD[3ZXW0GQR1XS
human SK-UT-1 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWHJcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg6OiEQvF2= MoT5V2FPT0WU
human Bel7402 NU\lbVdTWHKxbHnm[ZJifGmxbjDhd5NigQ>? MXu3NkBp M1S1TWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQnXsO|QxOiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzKEeubzDhd5NigSxiSVO1NF0xNjlizszN Mmn6NlI{OjB|NUS=
human A388 cell Ml;sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXr3XJpoUW6qaXLpeIlwdiCxZjDoeY1idiCDM{i4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PCEQvF2= NGG4SZVUSU6JRWK=
human SW982 cell M162W2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVPJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65PVkh|ryP NWXsR4o5W0GQR1XS

... Click to View More Cell Line Experimental Data

体内研究 Epothilone B 按 2.5 mg/kg–4 mg/kg 剂量作用于携带RPMI 8226细胞移植瘤的小鼠,延长小鼠寿命且抑制肿瘤生长。[4]Epothilone B 作用于携带前列腺癌细胞,包括DU145和PC3的移植瘤小鼠,也抑制肿瘤生长。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

微管蛋白聚合实验:

纯化牛脑微管蛋白(MTP), 包含约15%–20%微管相关蛋白。用于 Epothilone B-微管研究的buffer (MES buffer)含 0.1 M 2-吗啉乙磺酸(MES), 1 mM EGTA, 0.5 mM MgCl2, 和3 M 甘油,pH 为6.6。电子显微镜观察的样本置于碳覆盖火棉胶片包被的网格上(300 个网孔),用2%乙酸铀酰进行负染色。在有或无Epothilone B存在时, 使用分光光度计和恒温调节液体循环器。检测微管装配。温度维持在35oC,350 nm处检测到变浑浊状态(代表聚合物规模)。计算EC0.01。
细胞实验:[2]
- 合并
  • Cell lines: KB3-1, KBV-1, Hela, 和Hs578T细胞
  • Concentrations: 0–1 μM
  • Incubation Time: 24 小时测定有丝分裂停顿,72 小时测定细胞毒性。
  • Method: 为了测定有丝分裂受阻和畸变,细胞接种在48孔板中(用台酚蓝染色,测定细胞数)或置于盖玻片上。24小时后,用 Epothilone B处理细胞,在固定时间间隔记录。为了分析毒性, 测定细胞数,用台酚蓝染色记录阳性和阴性。 同时, 盖玻片和培养基上清液中等分的细胞混合,用溶于PBS的Hoechst 33342 染色。在有丝分裂受阻(停在G2-M期)和畸变的时候记录细胞。
    (Only for Reference)
动物实验:[4]
- 合并
  • Animal Models: 携带RPMI 8226 细胞移植瘤的小鼠
  • Dosages: 2.5 mg/kg–4 mg/kg
  • Administration: 静脉注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 102 mg/mL (200.91 mM)
Ethanol 102 mg/mL (200.91 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG400+0.5% Tween80+5% propylene glycol
5 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 507.68
化学式

C27H41NO6S

CAS号 152044-54-7
储存条件 粉状
溶于溶剂
别名 EPO906

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00496600 Completed Drug: Patupilone|Drug: RAD001 Refractory Malignancy University of Medicine and Dentistry of New Jersey|Novartis Pharmaceuticals|National Cancer Institute (NCI)|Rutgers The State University of New Jersey July 2007 Phase 1
NCT00442741 Withdrawn Drug: Patupilone|Drug: Patupilone + Omeprazole Solid Tumors Novartis Pharmaceuticals|Novartis July 2007 Phase 1
NCT00468260 Terminated Drug: Patupilone Advanced Malignancies Novartis Pharmaceuticals|Novartis May 2007 Phase 1
NCT00448396 Completed Drug: Patupilone Advanced Malignancies Novartis Pharmaceuticals|Novartis March 2007 Phase 1
NCT00426140 Completed Drug: Patupilone Advanced Malignancies|Solid Tumors Novartis Pharmaceuticals|Novartis August 2006 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂

Microtubule Associated Signaling Pathway Map

相关Microtubule Associated产品

Tags: 购买Patupilone (Epothilone B) | Patupilone (Epothilone B)供应商 | 采购Patupilone (Epothilone B) | Patupilone (Epothilone B)价格 | Patupilone (Epothilone B)生产 | 订购Patupilone (Epothilone B) | Patupilone (Epothilone B)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID